Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. It is characterized by the presence of malignant large cells.
Biomarker and diagnostic research for pancreatic large cell neuroendocrine carcinoma has been reported in the published literature.
No clinical trials have been registered for pancreatic large cell neuroendocrine carcinoma.
45 publications have been identified in PubMed for pancreatic large cell neuroendocrine carcinoma. Research spans Case Report / Case Series (38%), Epidemiology / Natural History (20%), and Clinical Trial Publication (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 17 | 38% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 5:32 PM UTC
Disease patterns and progression
9 |
20% |
Clinical study results | 7 | 16% |
Testing and diagnosis research | 6 | 13% |
Laboratory research | 6 | 13% |
Gujarathi R (2026). [PMID: 41968866](https://pubmed.ncbi.nlm.nih.gov/41968866/). *Cancer Med*. [Epidemiology / Natural History]
Tsai DR (2026). [PMID: 41855151](https://pubmed.ncbi.nlm.nih.gov/41855151/). *PLOS Digit Health*. [Epidemiology / Natural History]
Vocke CD (2026). [PMID: 41224595](https://pubmed.ncbi.nlm.nih.gov/41224595/). *Urologic oncology*. [Diagnostic / Biomarker]
Fu Y (2026). [PMID: 40934719](https://pubmed.ncbi.nlm.nih.gov/40934719/). *Annals of diagnostic pathology*. [Clinical Trial Publication]
Ankers Z (2026). [PMID: 41731695](https://pubmed.ncbi.nlm.nih.gov/41731695/). *The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society*. [Clinical Trial Publication]
Arends MJ (2026). [PMID: 41724188](https://pubmed.ncbi.nlm.nih.gov/41724188/). *Histopathology*. [Case Report / Case Series]
Auernhammer CJ (2026). [PMID: 41518601](https://pubmed.ncbi.nlm.nih.gov/41518601/). *The Journal of clinical endocrinology and metabolism*. [Clinical Trial Publication]
Zhang Y (2026). [PMID: 41638770](https://pubmed.ncbi.nlm.nih.gov/41638770/). *BMJ case reports*. [Diagnostic / Biomarker]
Walter TP (2026). [PMID: 41774886](https://pubmed.ncbi.nlm.nih.gov/41774886/). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. [Basic Science / Preclinical]
Sunakawa T (2026). [PMID: 41396400](https://pubmed.ncbi.nlm.nih.gov/41396400/). *Clinical journal of gastroenterology*. [Diagnostic / Biomarker]
AI-curated news mentioning pancreatic large cell neuroendocrine carcinoma
Updated Jul 29, 2026
The FIRST-NEC GFPC 01-2022 trial protocol outlines an externally controlled trial to evaluate first-line immunochemotherapy for advanced large cell neuroendocrine lung carcinomas. This study aims to enhance treatment strategies for this rare cancer type.
Recent research highlights metastatic large cell neuroendocrine carcinoma as a rare cause of hypopituitarism. This discovery may influence future diagnostic and treatment approaches for patients presenting with pituitary dysfunction.
A case report and literature review on primary large cell neuroendocrine carcinoma of the pulmonary artery has been published, contributing to the understanding of this rare cancer type. The findings may inform future research and clinical approaches.